Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic

In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until r...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lierop, Zoë YGJ, Toorop, Alyssa A, van Ballegoij, Wouter JC, Olde Dubbelink, Tom BG, Strijbis, Eva MM, de Jong, Brigit A, van Oosten, Bob W, Moraal, Bastiaan, Teunissen, Charlotte E, Uitdehaag, Bernard MJ, Killestein, Joep, van Kempen, Zoé LE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131403/
https://www.ncbi.nlm.nih.gov/pubmed/34240631
http://dx.doi.org/10.1177/13524585211028833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131403/
https://www.ncbi.nlm.nih.gov/pubmed/34240631
http://dx.doi.org/10.1177/13524585211028833

Ejemplares similares